FindTrial
Sign In

REMD-477

BIOLOGICAL9 trials

Sponsors

REMD Biotherapeutics, Inc., University of California, San Diego, Duke University, The University of Texas Health Science Center at San Antonio

Conditions

DiabetesGlucose Tolerance ImpairedHyperglycemia Drug InducedInsulin SensitivityType 1 DiabetesType 1 Diabetes MellitusType 2 DiabetesType 2 Diabetes Mellitus

Early Phase 1

Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM
CompletedNCT05093517
The University of Texas Health Science Center at San AntonioGlucose Tolerance Impaired, Insulin Sensitivity, Type 2 Diabetes
Start: 2021-11-10End: 2022-03-16Updated: 2024-08-09

Phase 1

Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus
CompletedNCT02455011
REMD Biotherapeutics, Inc.Diabetes, Type 2 Diabetes Mellitus
Start: 2015-09-30End: 2018-02-28Updated: 2018-04-10
Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus
CompletedNCT02715193
REMD Biotherapeutics, Inc.Diabetes, Type 1 Diabetes Mellitus
Start: 2016-03-31End: 2017-01-31Updated: 2017-02-07
Metabolic Pathways of GRA in Patients With Type 1 Diabetes
CompletedNCT03919617
University of California, San DiegoType 1 Diabetes Mellitus
Start: 2019-07-01End: 2022-05-31Updated: 2022-07-15
A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib
TerminatedNCT04253223
Duke UniversityHyperglycemia Drug Induced
Start: 2020-04-07End: 2021-05-05Updated: 2021-06-11
Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)
TerminatedNCT04330625
Duke UniversityHyperglycemia Drug Induced
Start: 2020-11-13End: 2021-05-05Updated: 2022-11-08
Combination GRA and SGLT-2i Treatment in Type 1 Diabetes
CompletedNCT04545411
University of California, San DiegoType 1 Diabetes
Start: 2021-02-22End: 2022-10-31Updated: 2023-01-23

Phase 2

Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus
CompletedNCT03117998
REMD Biotherapeutics, Inc.Type1 Diabetes Mellitus
Start: 2017-09-19End: 2021-03-05Updated: 2023-05-25
Effects of GRA in Patients With Type 1
Active, not recruitingNCT04779645
University of California, San DiegoType 1 Diabetes
Start: 2021-07-31End: 2025-12-31Updated: 2025-06-10

Related Papers

Effect of a glucagon receptor antibody (REMD‐477) in type 1 diabetes: A randomized controlled trial
Diabetes Obesity and Metabolism2017-12-2862 citations